Hazard Identification

Availability of Hazard Identification Materials for 1,2,4-Trichlorobenzene and Announcement of the Carcinogen Identification Committee Meeting

Availability of hazard identification materials for 1,2,4-trichlorobenzene and announcement of the Carcinogen Identification Committee meeting.

Final Hazard Identification Document for Phenol

The final hazard identification document "Evidence on the Developmental and Reproductive Toxicity of Phenol" was released for public comment.

Availability of the Final Hazard Identification Documents for 1,2-Epoxybutane and Verapamil

Availability of the final hazard identification documents on the carcinogenicity of 1,2-epoxybutane and verapamil.

Request for Information on Chloroform, a Chemical to be Considered by the DART Identification Committee

Request for information on chloroform to be considered by OEHHA's Science Advisory Board's Developmental and Reproductive Toxicant (DART) Identification Committee.

October 16, 2003 Meeting of the Science Advisory Board's Developmental and Reproductive Toxicant (DART) Identification Committee

October 16, 2003 Meeting of the Science Advisory Board's Developmental and Reproductive Toxicant (DART) Identification Committee

October 17, 2003 Meeting of the Science Advisory Board's Carcinogen Identification Committee

October 17, 2003 Meeting of the Science Advisory Board's Carcinogen Identification Committee

Draft Hazard Identification Documents for Propachlor and Phenol

Draft Hazard Identification Documents on the Reproductive Toxicity of Propachlor and Phenol

Draft and FINAL Hazard Identification Documents for Chloral Hydrate

Draft and final hazard identification documents for the carcinogenicity of chloral hydrate.

Request for Information on Chemicals to be Considered by the CIC: Statins

Request for information on chemicals to be considered by the OEHHA Science Advisory Board's Carcinogen Identification Committee: Statins

Background for the December 17, 2002 Carcinogen Identification Committee Meeting Agenda Item: Consideration of Request to Review Statin Drugs as a Group for Subsequent Listing

Background for the December 17, 2002 Carcinogen Identification Committee meeting agenda item: Consideration of request to review statin drugs as a group for subsequent listing.

Pages